(Q42239419)

English

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial

scientific article published on 23 November 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

based on heuristic

inferred from title

Martin Tolstrup

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

object named as

Jesper Bonde

5

0 references

Ole Schmeltz Søgaard

object named as

Ole S Søgaard

8

0 references

Lars Østergaard

object named as

Lars Østergaard

7

0 references

Merete Storgaard

object named as

Merete Storgaard

2

0 references

author name string

Lars Toft

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Martin Müller

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Peter Sehr

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

23 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

209

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1165-1173

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Global burden of human papillomavirus and related diseases.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Quadrivalent human papillomavirus vaccine

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Human papillomavirus-related disease in people with HIV

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Measuring serum antibody to human papillomavirus following infection or vaccination.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Potential mechanisms for HPV vaccine-induced long-term protection

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Estrogens augment cell surface TLR4 expression on murine macrophages and regulate sepsis susceptibility in vivo

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Human immunodeficiency virus infection alters tumor necrosis factor alpha production via Toll-like receptor-dependent pathways in alveolar macrophages and U1 cells

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

High-throughput SNP-based authentication of human cell lines

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

High-throughput detection and multiplex identification of cell contaminations

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT657

21 January 2018

Identifiers

10.1093/INFDIS/JIT657

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42239419&oldid=1939737122"